The BA.3.2 variant, commonly referred to as the Cicada variant, is a descendent of the BA.3 subvariant of Omicron that emerged in 2022. First identified in South Africa in November 2024, this variant has raised eyebrows due to its significant number of mutations—approximately 70 to 75 in its spike protein. As it spreads, particularly in the United States and over 20 other countries, health experts are closely monitoring its impact on public health.

Initial reports indicate that common symptoms associated with the Cicada variant include cough, fever or chills, sore throat, congestion, shortness of breath, loss of smell or taste, fatigue, headache, and gastrointestinal issues such as diarrhea or vomiting. While these symptoms may sound alarming, it is important to note that current evidence suggests that the BA.3.2 variant does not cause more severe illness compared to earlier variants of COVID-19.

Dr. Adolfo García-Sastre, a prominent health expert, reassures the public by stating, “There’s no evidence that BA.3.2 is causing more severe disease or hospitalizations in countries where it’s more widespread.” Most cases of the Cicada variant appear to be mild to moderate, resembling flu-like illness, especially among vaccinated individuals. This is a crucial point as it underscores the importance of vaccination in mitigating severe outcomes.

Despite the presence of numerous mutations, vaccines are still expected to provide strong protection against severe disease, even if breakthrough infections occur. Health authorities emphasize that staying up to date with vaccinations is essential, particularly as the variant spreads in crowded or poorly ventilated spaces. Observers note that the symptoms linked to the Cicada variant remain largely consistent with previous COVID-19 strains, which can help in identifying and managing cases effectively.

As the Cicada variant continues to rise in prevalence, particularly in 25 states across the U.S., health experts are urging the public to remain vigilant. They recommend taking precautions in crowded settings and maintaining good hygiene practices. Most cases remain mild and can be managed at home with rest and hydration, which is a comforting thought for many.

However, there are still concerns about the effectiveness of current vaccines against this variant due to its multiple mutations. Some experts have pointed out that while vaccines may not be as effective against the Cicada variant, they still play a critical role in preventing severe disease. As the situation evolves, health authorities are actively monitoring the BA.3.2 variant to ensure public safety.

In summary, while the emergence of the Cicada variant brings new challenges, health experts remain optimistic about the ability to manage it effectively. The focus remains on vaccination and public health measures to curb its spread. As we navigate this new phase of the pandemic, staying informed and taking appropriate precautions will be key to protecting ourselves and our communities.

The post Cicada COVID Variant Symptoms: What You Need to Know appeared first on crypto.

The cicada COVID variant, officially designated as BA.3.2, is causing alarm as it spreads across the United States. This heavily mutated strain of SARS-CoV-2 has been detected in at least 25 states as of February 2026, raising concerns about its potential to evade immunity from vaccines and prior infections.

First identified in South Africa in November 2024, BA.3.2 has since made its way to at least 23 countries worldwide. The variant is characterized by an astonishing 70 to 75 mutations in its spike protein, which may significantly reduce the effectiveness of current vaccines against infection, although they are still expected to provide protection against severe disease.

Andrew Pekosz, Ph.D., highlights the variant’s numerous mutations, stating, “It has a lot of mutations that may cause it to look different to your immune system.” This adaptability poses a challenge for public health officials as they work to monitor and control its spread.

Despite these concerns, experts like Dr. Adolfo García-Sastre reassure that there is currently no evidence suggesting that BA.3.2 causes more severe disease or hospitalizations compared to previous strains. This is a critical point, as it suggests that while the variant may be more transmissible, it does not necessarily lead to worse health outcomes.

As of February 2026, BA.3.2 accounts for approximately 30% of cases in Denmark, Germany, and the Netherlands, indicating its rapid spread in Europe as well. In the U.S., a mere 3.7% of sewage samples nationwide have shown the presence of BA.3.2, but this figure may rise as more testing is conducted.

The variant’s name, ‘cicada,’ reflects its unusual emergence pattern, reminiscent of the insect’s lifecycle. This nomenclature underscores the unpredictable nature of viral evolution, especially in the context of a pandemic that has already seen numerous variants.

Symptoms associated with BA.3.2 include cough, fever, sore throat, congestion, and loss of smell or taste, among others. These symptoms are consistent with common COVID-19 manifestations, making it essential for individuals to remain vigilant.

Looking ahead, the exact reasons for the resurgence of BA.3.2 remain unclear, and the long-term impact on public health is uncertain. Details remain unconfirmed, but health authorities continue to monitor the situation closely.

As vaccination efforts persist, experts emphasize that vaccination is still crucial in limiting cases. Pekosz states, “Vaccination is still going to help limit cases,” reinforcing the importance of maintaining high vaccination rates to combat the evolving threat of COVID-19 variants like BA.3.2.

The post Cicada COVID Variant: The Emerging BA.3.2 Threat appeared first on crypto.